At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

FLT3 Mutated Acute Myeloid Leukemia Treatment Study

Clinical Trial Title: 
Phase III randomized study of crenolanib versus midostaurin administered following induction chemotherapy and consolidation therapy in newly diagnosed subjects with FLT3 mutated acute myeloid leukemia.
Clinical Trial Protocol ID: 
18100805
Clinical Trial Investigator Name: 
Melissa Larson, MD
Clinical Trial Protocol Description: 

During the treatment period, newly diagnosed acute myeloid leukemia subjects with FLT3 mutation will receive cytarabine and daunorubicin as induction chemotherapy, followed by crenolanib for subjects randomized to arm A (the crenolanib treatment arm) or midostaurin for subjects randomized to arm B (the control arm).

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have a confirmed diagnosis of de novo AML according to World Health Organization (WHO) 2016 classification.
  • Are between 18 and 60 years of age.
  • Have adequate hepatic function within 48 hours prior to induction chemotherapy, defined as:
    • Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN)
    • Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN
    • Serum alanine aminotransferase (ALT) ≤ 3.0 x ULN
  • Have adequate renal functions within 48 hours prior to induction chemotherapy, defined as:
    • Serum creatinine ≤ 1.5x ULN or glomerular filtration rate > 50 mL/min
  • Have an ECOG performance status within 48 hours prior to induction chemotherapy ≤ 3.
  • Are eligible for intensive cytarabine/daunorubicin (7+3) chemotherapy.

All potential subjects for the trial will undergo a pre-screening process.

This is a partial list of elgibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Email: 
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office